An orally-active, next-generation S1P1 agonist in clinical development for autoimmune diseases. Data from completed Phase 1b study demonstrated best-in-class potential with rapid onset of T cell modulation at an extremely low dose and excellent safety and tolerability. CBP-307 is currently in Phase 2 clinical development for inflammatory...
Learn More>>A highly potent antibody against IL-4Rα, a receptor for both IL-4 and IL-13, two key Th2 cytokines in allergic inflammation. Phase 1b study in patients with moderate-to-several atopic dermatitis showed that four-week treatment of CBP-201 resulted in significant and rapid improvement in all disease metrics including skin lesion and pruritus...
Learn More>>A small molecule inhibitor of a G-protein coupled receptor involved in pruritus associated with chronic skin inflammation. It is highly efficacious in preclinical pruritus models via a novel mechanism of action and thus has the potential to be first of a new class of anti-pruritus drug. Preclinical development is currently underway.
Learn More>>Connect Biopharmaceuticals is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. We leverage our expertise in the biology of T cell modulation to build a strong portfolio of innovative product candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Our aim is to improve the lives of patients in China and around the world by creating novel medicines with better efficacy and fewer side effects.
Copyright: Suzhou Connect Biopharmaceuticals, Ltd. 苏ICP备17002143号
Technical support: Epower
